Trial Profile
A Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Phase III Trial Assessing the Efficacy and Safety of ALK Grass Tablet in Subjects With Seasonal Grass Pollen Induced Rhiniconjunctivitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2023
Price :
$35
*
At a glance
- Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
- Indications Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors ALK-Abello
- 27 Feb 2023 Results assessing the Onset of clinicaleffect was evaluated for grass, ragweed, tree, and house dust mite (HDM)sublingual immunotherapy (SLIT)-tablets from NCT00227279, NCT00783198 and EudraCT2015-004821-15 studies, presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 02 Mar 2012 Two-year follow-up results published in the March issue of the Journal of Allergy and Clinical Immunology, according to an ALK Abello media release.
- 28 Jan 2012 Two-year follow-up results published in the Journal of Allergy and Clinical Immunology.